Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the influence of the glycone space on the therapeutic potential of sp2-iminoglycolipids

  • Padilla, M. Carmen
  • Rodríguez Marín, Rocío
  • González Bakker, Aday
  • Khan, Adam N.
  • Bastardo, Mariana
  • Padrón, José M.
  • Martín Loro, Francisco
  • Arroba, Ana I.
  • García-Hernández, Raquel
  • Pérez-Victoria, José M.
  • García Fernández, José Manuel
  • Sánchez-Fernández, Elena M.
  • Ortiz Mellet, Carmen
Extensive structure-activity relationship studies performed on sp2-iminoglycolipids revealed the fundamental role played by a linear dodecylsulfide/sulfonyl aglycone chain on the anticancer, antiparasitic and immunomodulatory activities. However, the influence of structural modifications within the glycone region on the therapeutic performance remains largely underexplored. To address this gap, we have designed and stereoselectively synthesized a novel series of sp2-iminoglycolipids incorporating targeted modifications to the glycomimetic unit. These include C2 deoxygenation, bioisosteric replacement of the hydroxyl group with fluorine, and selective installation of aromatic hydrocarbons at the O3 position. Among the synthesized compounds, the fluorinated derivative (1R)-2-deoxy-1-S-dodecyl-2-fluoro-3-O-(p-fluorobenzyl)-5N,6O-oxomethylidene-1-sulfonylnojirimycin emerged as a promising multi-target candidate. Live-cell imaging in human cervical cancer (HeLa) cells revealed phenotypic markers characteristic of apoptotic cell death. Furthermore, clonogenic assays showed a significant, concentration-dependent reduction in the formation of cancer cell colonies, indicating impairment of tumor cell reproductive viability. Altogether, these data support a potent antiproliferative activity. This compound also exhibited strong antiparasitic activity, effectively inhibiting the growth of Leishmania donovani amastigotes at low micromolar concentrations. Additionally, it showed notable anti-inflammatory properties in microglial cells by downregulating the NLRP3 inflammasome signaling pathway following inflammatory stimulation, as evidenced by reduced caspase-1 activation and suppressed IL-1β release., This work was supported by grants funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación MICIU/AEI/10.13039/501100011033 and “ERDF/EU” (grant numbers PID2022-141034OB-C21 to COM and EMSF; PID2022-138474OB-I00 to JMPV; PID2021-123059OB-I00 to JMP; PID2021-124247OB-C21 to JMGF). RRM is a FPI fellow (Grant number, PREP2022-000217). EMSF thanks the VII Plan Propio de Investigación y Transferencia from the University of Seville (VIIPPIT-2022-V.1, Modality A2). Technical assistance from the research support services of the University of Seville (CITIUS) is also acknowledged. AGB thanks the Asociación Española Contra el Cáncer (AECC) de Santa Cruz de Tenerife for predoctoral grant PRDTF233958GONZ. AIA was supported by grants from Instituto de Salud Carlos III (PI22/01718)., Peer reviewed
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks

  • Díaz-Paredes, E.
  • Martín Loro, Francisco
  • Rodríguez-Marín, R.
  • Gómez Jaramillo, María Laura
  • Sánchez-Fernández, Elena M.
  • Carrillo-Carrión, Carolina
  • Arroba Espinosa, Ana Isabel
Background/Objectives: Diabetic retinopathy is an ocular disease caused by changes in the expression of inflammatory mediators and increased oxidative stress in the retina and is the leading cause of vision loss in diabetic patients. Currently, there is no treatment capable of reversing retinal damage, which represents a significant burden on the quality of life of patients. (1R)-1-Dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin stands outs as a prototype of the sp2 -iminoglycolipids family for its beneficial neuroprotective effect against this chronic eye disease. Critical issues related to the low solubility and bioavailability of this glycolipid in biological settings are overcome by its encapsulation in a Zeolitic-Imidazolate Framework (ZIF) structure, resulting in homogeneous and biocompatible GlycoZIF nanoparticles. Cell studies show an enhanced cellular uptake compared with the free glycolipid, and importantly, its bioactivity is preserved once released inside cells. Methods: Extensive in vitro and ex vivo assays with diabetic retinopathy models unveil the mechanistic pathways of the designed GlycoZIF. Results: A reduction in proinflammatory mediators, increased heme oxygenase-1 level, inhibition of NLRP3 inflammasome, and reduced reactive gliosis is shown. Conclusions: These findings demonstrate for the first time the potential of Glyco-modified ZIFs for the treatment of diabetes-related ocular problems by controlling the immune-mediated inflammatory response.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus

  • Cano Cano, Fátima
  • Lara Barea, Almudena
  • Cruz Gómez, Álvaro Javier
  • Martín Loro, Francisco
  • Gómez Jaramillo, María Laura
  • González Montelongo, María del Carmen
  • Roca Rodríguez, María del Mar
  • Beltrán Camacho, Lucía
  • Forero, Lucía
  • González Rosa, Javier Jesús
  • Durán Ruiz, María del Carmen
  • Arroba Espinosa, Ana Isabel
  • Aguilar Diosdado, Manuel
Background: Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ from those of MS, such as pancreatic β-cell failure in T1DM and demyelination in the central nervous system (CNS) in MS, both pathologies are considered as autoimmune-related diseases with shared pathogenic pathways, which include autophagy, inflammation and degeneration, among others. Considering the challenges in obtaining pancreatic β-cells and CNS tissue from patients with T1DM and MS, respectively, it is fundamental to explore alternative methods for evaluating disease status. Proteomic analysis of peripheral blood mononuclear cells (PBMCs) is an ideal approach for identifying novel and potential biomarkers for both autoimmune diseases. Methods: We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. Results: A total of 2476 proteins were differentially expressed in PBMCs from patients with T1DM and MS patients compared with those form healthy controls (H). Predictive analysis highlighted 15 common proteins, up- or downregulated in PBMCs from patients with T1DM and MS patients vs. healthy controls, involved in the immune system activity (BTF3, TTR, CD59, CSTB), diseases of the neuronal system (TTR), signal transduction (STMN1, LAMTOR5), metabolism of nucleotides (RPS21), proteins (TTR, ENAM, CD59, RPS21, SRP9) and RNA (SRSF10, RPS21). In addition, this study revealed both shared and distinct molecular patterns between the two conditions. Conclusions: Compared with H, patients with T1DM and MS presented a specific expression pattern of common proteins has been identified. This pattern underscores the shared mechanisms involved in their immune responses and neurological complications, alongside dysregulation of the autophagy pathway. Notably, CSTB has emerged as a differential biomarker, distinguishing between these two autoimmune diseases.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Arylphthalide Delays Diabetic Retinopathy via Immunomodulating the Early Inflammatory Response in an Animal Model of Type 1 Diabetes Mellitus

  • Martín Loro, Francisco
  • Can Cano, Fátima
  • Ortega Agüera, María Jesús
  • Cuevas, Belén
  • Gómez Jaramillo, María Laura
  • González Montelongo, María del Carmen
  • Freisenhausen, Jan Cedric
  • Lara Barea, Almudena
  • Campos Caro, Antonio
  • Zubía Mendoza, Eva
  • Aguilar Diosdado, Manuel
  • Arroba Espinosa, Ana Isabel
Diabetic retinopathy (DR) is one of the most prevalent secondary complications associated with diabetes. Specifically, Type 1 Diabetes Mellitus (T1D) has an immune component that may determine the evolution of DR by compromising the immune response of the retina, which is mediated by microglia. In the early stages of DR, the permeabilization of the blood–retinal barrier allows immune cells from the peripheral system to interact with the retinal immune system. The use of new bioactive molecules, such as 3-(2,4-dihydroxyphenyl)phthalide (M9), with powerful anti-inflammatory activity, might represent an advance in the treatment of diseases like DR by targeting the immune systems responsible for its onset and progression. Our research aimed to investigate the molecular mechanisms involved in the interaction of specific cells of the innate immune system during the progression of DR and the reduction in inflammatory processes contributing to the pathology. In vitro studies were conducted exposing Bv.2 microglial and Raw264.7 macrophage cells to proinflammatory stimuli for 24 h, in the presence or absence of M9. Ex vivo and in vivo approaches were performed in BB rats, an animal model for T1D. Retinal explants from BB rats were cultured with M9. Retinas from BB rats treated for 15 days with M9 via intraperitoneal injection were analyzed to determine survival, cellular signaling, and inflammatory markers using qPCR, Western blot, or immunofluorescence approaches. Retinal structure images were acquired via Spectral-Domain–Optical Coherence Tomography (SD-OCT). Our results show that the treatment with M9 significantly reduces inflammatory processes in in vitro, ex vivo, and in vivo models of DR. M9 works by inhibiting the proinflammatory responses during DR progression mainly affecting immune cell responses. It also induces an anti-inflammatory response, primarily mediated by microglial cells, leading to the synthesis of Arginase-1 and Hemeoxygenase-1(HO-1). Ultimately, in vivo administration of M9 preserves the retinal integrity from the degeneration associated with DR progression. Our findings demonstrate a specific interaction between both retinal and systemic immune cells in the progression of DR, with a differential response to treatment, mainly driven by microglia in the anti-inflammatory action. In vivo treatment with M9 induces a switch in immune cell phenotypes and functions that contributes to delaying the DR progression, positioning microglial cells as a new and specific therapeutic target in DR.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Fluoro-labelled sp2-iminoglycolipids with immunomodulatory properties

  • Padilla Pérez, M. Carmen
  • Sánchez Fernández, Elena M.
  • González Bakker, Aday
  • Puerta, Adrián
  • Martín Loro, Francisco
  • García Fernández, José Manuel
  • Padrón, José M.
  • Arroba Espinosa, Ana Isabel
  • Ortiz Mellet, Carmen
The unique electronic properties of the fluorine atom make its strategic incorporation into a bioactive compound a very useful tool in the design of drugs with optimized pharmacological properties. In the field of the carbohydrates, its selective installation at C2 position has proven particularly interesting, some 2-deoxy-2-fluorosugar derivatives being currently in the market. We have now transferred this feature into immunoregulatory glycolipid mimetics that contain a sp2-iminosugar moiety, namely sp2-iminoglycolipids (sp2-IGLs). The synthesis of two epimeric series of 2-deoxy-2-fluoro-sp2-IGLs, structurally related to nojirimycin and mannonojirimycin, has been accomplished by sequential Selectfluor-mediated fluorination and thioglycosidation of sp2-iminoglycals. Exclusively the α-anomer is obtained regardless of the configurational profile of the sp2-IGL (D-gluco or D-manno), highlighting the overwhelming anomeric effect in these prototypes. Notably, the combination of a fluorine atom at C2 and an α-oriented sulfonyl dodecyl lipid moiety in compound 11 led to remarkable anti-proliferative properties, featuring similar GI50 values than the chemotherapy drug Cisplatin against several tumor cell lines and better selectivity. The biochemical data further evidence a strong reduction of the number of tumor cell colonies and apoptosis induction. Mechanistic investigations revealed that this fluoro-sp2-IGL induces the non-canonical activation mode of the mitogen-activated protein kinase signaling pathway, causing p38α autoactivation under an inflammatory context., 19 páginas